Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Juan Camilo Falla"'
Autor:
Luis Gabriel Parra-Lara, Juan Camilo Falla-Martínez, Daniel Francisco Isaza-Pierotti, Diana Marcela Mendoza-Urbano, Andrés R. Tangua-Arias, Juan Carlos Bravo, Luis Eduardo Bravo, Ángela R. Zambrano
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundGastric adenocarcinoma (GA) has changed in recent decades. Cancer estimates are often calculated from population-based cancer registries, which lack valuable information to guide decision-making (clinical outcomes). We describe the trends i
Externí odkaz:
https://doaj.org/article/8c1709c1593946a3a34fbab2376027fd
Autor:
Ramiro Manzano-Nunez, Claudia P. Orlas, Maria Paula Naranjo, Federico Coccolini, Juan P. Herrera-Escobar, Joseph J. DuBose, Camilo Jose Salazar, Samuel M. Galvagno, Michael W. Parra, Juan Camilo Falla-Martinez, Carlos A. Ordoñez, Ernest E. Moore, Julian Chica, Alberto García, Valeria Lopez-Castilla, Paula Ferrada, Alvaro I. Sánchez, Luis Eduardo Calderón-Tapia, Massimo Sartelli, Tal M. Hörer
Publikováno v:
European journal of trauma and emergency surgery : official publication of the European Trauma Society. 44(4)
Current literature shows the association of post-intubation hypotension and increased odds of mortality in critically ill non-trauma and trauma populations. However, there is a lack of research on potential interventions that can prevent or ameliorat
Autor:
Fernando Rosso, Juan Camilo Falla, Luis Gabriel Parra-Lara, Ángela R Zambrano, Luis Eduardo Bravo, Juan C. Bravo
Publikováno v:
Open Forum Infectious Diseases
Background Gastric carcinoma (GC) has been associated with the presence of Helicobacter pylori infection. The infection rates vary according to geographic region and the majority of infected persons remain asymptomatic. Recent studies have suggested
Autor:
Carol Nieroda, Armando Sardi, Kimberly Studeman, Jennifer Francis, William Jimenez, Ryan MacDonald, Juan Camilo Falla
Publikováno v:
Journal of Clinical Oncology. 31:e15123-e15123
e15123 Background: Vascular endothelial growth factor receptor 2 (VEGFR-2) is considered a prognostic factor and treatment target for metastatic colorectal and ovarian cancer. Peritoneal Carcinomatosis (PC) from appendiceal cancer is a rare malignanc